Literature DB >> 2328504

Development and characterization of pediatric osteosarcoma xenografts.

W H Meyer1, J A Houghton, P J Houghton, B L Webber, E C Douglass, A T Look.   

Abstract

Of 33 surgical specimens of osteosarcoma obtained from 24 patients, eight were established as transplantable tumor lines in immune-deprived CBA/CaJ inbred mice. Each line retained the histological characteristics of the corresponding primary tumor and produced human lactate dehydrogenase isozymes. Volume doubling times, which ranged from a mean of 12.3 +/- 5.6 to 39.3 +/- 9.8 days, were stable for individual lines over multiple passages. Flow cytometric analysis indicated similar cellular DNA content values in the primary human tumors and established xenograft lines; the presence of two separate stem lines, as in the original tumors, was observed in the laboratory models. Comparison of two methods of immune deprivation indicated that thymectomy, whole-body irradiation, and bone marrow reconstitution was associated with a higher rate of successful engraftment than was thymectomy, 1-beta-D-arabinofuranosylcytosine treatment, and whole-body irradiation. Bone marrow-reconstituted mice also showed less variability in tumor volume doubling time. We conclude that osteosarcoma can be heterotransplanted into bone marrow-reconstituted mice with a relatively high success rate and that the xenografts retain features characteristic of the tumors of origin. The availability of these models should prove useful in the development of new therapeutic regimens and in understanding the biology of osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328504

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Challenges and Opportunities for Childhood Cancer Drug Development.

Authors:  Peter J Houghton; Raushan T Kurmasheva
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

2.  Establishment of human osteosarcoma cell lines with high metastatic potential to lungs and their utilities for therapeutic studies on metastatic osteosarcoma.

Authors:  Kenji Kimura; Tetsuhiro Nakano; Yong-Bum Park; Masachika Tani; Hiroyuki Tsuda; Yasuo Beppu; Hideshige Moriya; Jun Yokota
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 3.  Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).

Authors:  M Smith; P T Ho
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Human pancreatic leiomyosarcoma (PZX-7) growing as a serially transplantable xenograft in immunosuppressed mice.

Authors:  A Zalatnai; J Bocsi; T Csákány; T Fekete; J Lásztity
Journal:  Int J Pancreatol       Date:  1999-08

5.  A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies.

Authors:  S F Jia; L L Worth; E S Kleinerman
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

6.  Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.

Authors:  H S Friedman; P J Houghton; S C Schold; S Keir; D D Bigner
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Human osteosarcoma xenografts and their sensitivity to chemotherapy.

Authors:  Skjalg Bruheim; Oyvind S Bruland; Knut Breistol; Gunhild M Maelandsmo; Oystein Fodstad
Journal:  Pathol Oncol Res       Date:  2004-09-25       Impact factor: 3.201

8.  The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

Authors:  Raushan T Kurmasheva; Lorina Dudkin; Catherine Billups; Larisa V Debelenko; Christopher L Morton; Peter J Houghton
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

9.  Biological properties and gene expression associated with metastatic potential of human osteosarcoma.

Authors:  Tetsuhiro Nakano; Masachika Tani; Yasunori Ishibashi; Kenji Kimura; Yong-Bum Park; Natsuko Imaizumi; Hiroyuki Tsuda; Kazuhiko Aoyagi; Hiroki Sasaki; Susumu Ohwada; Jun Yokota
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.

Authors:  P J Houghton; P J Cheshire; L Myers; C F Stewart; T W Synold; J A Houghton
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.